Trexquant Investment LP Purchases New Stake in SI-BONE, Inc. (NASDAQ:SIBN)

Trexquant Investment LP bought a new stake in SI-BONE, Inc. (NASDAQ:SIBN - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 87,783 shares of the company's stock, valued at approximately $1,231,000. Trexquant Investment LP owned approximately 0.21% of SI-BONE as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Jane Street Group LLC boosted its holdings in SI-BONE by 29.0% in the 3rd quarter. Jane Street Group LLC now owns 77,359 shares of the company's stock valued at $1,081,000 after purchasing an additional 17,410 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of SI-BONE by 9.4% in the third quarter. Franklin Resources Inc. now owns 20,220 shares of the company's stock valued at $265,000 after buying an additional 1,745 shares in the last quarter. State Street Corp grew its holdings in SI-BONE by 5.1% during the third quarter. State Street Corp now owns 1,081,871 shares of the company's stock worth $15,125,000 after acquiring an additional 52,972 shares during the period. Harbor Capital Advisors Inc. raised its position in SI-BONE by 35.5% in the fourth quarter. Harbor Capital Advisors Inc. now owns 841,045 shares of the company's stock worth $11,791,000 after acquiring an additional 220,555 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in SI-BONE by 14.7% in the third quarter. JPMorgan Chase & Co. now owns 177,793 shares of the company's stock valued at $2,486,000 after acquiring an additional 22,732 shares during the period. 98.11% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analysts Forecast Growth

SIBN has been the topic of a number of recent analyst reports. Needham & Company LLC upped their price target on shares of SI-BONE from $20.00 to $24.00 and gave the stock a "buy" rating in a research note on Tuesday, February 25th. Truist Financial restated a "buy" rating and set a $22.00 target price (up from $18.00) on shares of SI-BONE in a research report on Tuesday, February 25th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 price target on shares of SI-BONE in a research report on Tuesday, February 25th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $24.40.

SI-BONE Price Performance

NASDAQ:SIBN traded down $0.29 during mid-day trading on Tuesday, hitting $13.07. 121,814 shares of the company's stock traded hands, compared to its average volume of 362,784. SI-BONE, Inc. has a 1 year low of $11.70 and a 1 year high of $19.16. The company has a market cap of $554.86 million, a PE ratio of -14.21 and a beta of 1.02. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. The firm's 50 day simple moving average is $15.55 and its 200 day simple moving average is $14.64.

SI-BONE (NASDAQ:SIBN - Get Free Report) last issued its quarterly earnings data on Monday, February 24th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.05. The firm had revenue of $49.00 million during the quarter, compared to the consensus estimate of $48.87 million. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. Sell-side analysts expect that SI-BONE, Inc. will post -0.78 EPS for the current year.

Insider Buying and Selling at SI-BONE

In other SI-BONE news, insider Anthony J. Recupero sold 3,311 shares of SI-BONE stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $14.15, for a total value of $46,850.65. Following the completion of the sale, the insider now owns 284,555 shares in the company, valued at $4,026,453.25. The trade was a 1.15 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Michael A. Pisetsky sold 3,128 shares of the company's stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $14.14, for a total transaction of $44,229.92. Following the transaction, the senior vice president now directly owns 244,878 shares of the company's stock, valued at $3,462,574.92. This trade represents a 1.26 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 6,776 shares of company stock worth $96,644. Corporate insiders own 3.90% of the company's stock.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.